AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26510448
Drug: Metformin vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin vs Placebo
Trial: 16601292
Drug: Subsequent endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent endocrine therapy after fulvestrant
Trial: 3161487
Drug: tocainide HC1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tocainide HC1 900 mg/day
Trial: 30501605
Drug: BPF Phyto
RxNorm normalized name: phytol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPF Phyto (phytosomal formulation of bergamot polyphenolic fraction)
Trial: 20383510
Drug: Labetalol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (2.5 mg in 20 ml saline)
Trial: 21468614
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml saline)
Trial: 20383510
Drug: Labetalol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (5 mg in 20 ml saline)
Trial: 26365144
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave treatment (ESWT)
Trial: 17432639
Drug: Antondine injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antondine injection (Control)
Trial: 10641772
Drug: APD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APD treatment
Trial: 9032854
Drug: Gamma Knife
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma Knife radiosurgery with a mean dose of 12.1 Gy
Trial: 1647919
Drug: Continuous total
RxNorm normalized name: Zinc Oxide 7.25 g in 100 g / Titanium Dioxide 3.5 g in 100 g TOPICAL SPRAY [Kids SPF50 Plus Mineral Sunscreen Continuous Totally Tropical]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous total parenteral nutrition (infused continuously over 24 h)
Trial: 1647919
Drug: Cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic total parenteral nutrition (infused between 22.00 and 10.00 hours)
Trial: 1647919
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Continuous and Cyclic total parenteral nutrition)
Trial: 3910159
Drug: Lay open
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lay open treatment (n = 26)
Trial: 3910159
Drug: Excision treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excision treatment (n = 21)
Trial: 27627782
Drug: Naltrexone hydrochloride,
RxNorm normalized name: Naltrexone Hydrochloride, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone hydrochloride, 50 mg/d
Trial: 15762190
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA treatment (50 mg/day for 9 days)
Trial: 14696887
Drug: Ketorolac 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.35 mg x kg(‐1)
Trial: 14696887
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg x kg(‐1)
Trial: 14696887
Drug: Both Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Ketorolac and Morphine
Trial: 1476266
Drug: Oral defibrotide
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral defibrotide in association with diet and oral antidiabetic drugs
Trial: 1476266
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and antidiabetic agents (Control)
Trial: 1476266
Drug: Oral defibrotide
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral defibrotide
Trial: 6435481
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (iv NTG) infusion at 0.5 microgram . kg‐1 . min‐1 for 20 min prior to induction of anesthesia and throughout the study
Trial: 29421218
Drug: Topically delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically delivered kynurenic acid cream
Trial: 27863615
Drug: Lavender essence
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender essence inhalation (2 drops at 4-5, 6-7, 8-9 cm cervical dilation)
Trial: 24672938
Drug: HAART alone
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART alone (treatment group)
Trial: 24672938
Drug: HAART combined
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART combined with Qiling Decoction (combination group)
Trial: 8648209
Drug: Saquinavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir (600 mg, 3 times/day) alone or in combination with zidovudine (200 mg, 3 times/day)
Trial: 8648209
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of saquinavir, zidovudine, and dideoxycytidine
Trial: 7042029
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (n = 46)
Trial: 7042029
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole (n = 51)
Trial: 25684005
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration of 1.0 ng/mL (group R1.0)
Trial: 25684005
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration of 1.5 ng/mL (group R1.5)
Trial: 25684005
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration of 0 ng/mL (group R0)
Trial: 25684005
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration of 0.5 ng/mL (group R0.5)
Trial: 21836540
Drug: Daclizumab induction
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab induction with tacrolimus/mycophenolate combination
Trial: 16772244
Drug: Low-fat milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat milk (240 mL, 12 g of lactose)
Trial: 9269944
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of benazepril (10 mg) and low-dose amlodipine (2.5 mg)
Trial: 3661923
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg fentanyl
Trial: 27265743
Drug: Durvalumab or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab or Tremelimumab as monotherapy
Trial: 25953222
Drug: Norepinephrine (0.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (0.66 mg/L)
Trial: 25953222
Drug: Epinephrine (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.33 mg/L)
Trial: 19478257
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (250 mg, twice daily) added to metronidazole
Trial: 15573850
Drug: Dexamethasone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (3 doses of 6 mg IV)
Trial: 9129063
Drug: Baseline HIV-1
RxNorm normalized name: petrolatum 1 MG/MG [Vaseline]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HIV-1 RNA level >100,000 copies/mL
Trial: 26231850
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with focus on lifestyle (n = 90)
Trial: 26231850
Drug: 10-session, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session, 1.5 h/week group treatment with focus on parenting (n = 45)
Trial: 26231850
Drug: Same group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same group treatment as 2) with additional follow-up sessions (n = 45)
Trial: 23601801
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide (FA) implants
Trial: 14710100
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg vaginally administered isosorbide mononitrate
Trial: 11268494
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide (1000 mg/m2 day 1), epidoxorubicin (60 mg/m2 day 1), and vincristine (1.4 mg/m2 day 1) every 14 days for six cycles followed by cisplatin (40 mg/m2 days 1 & 2) and etoposide (100 mg/m2 days 1‐3) every 14 days for four cycles, with prophylactic filgrastim (300 mcg subcutaneously from day 5 to day 10)
Trial: 11268494
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide, epidoxorubicin, and vincristine followed by cisplatin and etoposide
Trial: 3235816
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DZ MM i.v. + placebo i.m.
Trial: 3235816
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DZ i.v. + placebo i.m.
Trial: 3235816
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DZ MM i.m. + placebo i.v.
Trial: 3235816
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DZ i.m. + placebo i.v.
Trial: 24716668
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium-enriched yeast (SelenoPrecise®) daily for 12 months
Trial: 24716668
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets daily for 12 months
Trial: 18398972
Drug: Elevated breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated breast milk sodium concentration (> or =13 mmol/L) at 4 months
Trial: 14666354
Drug: Triancinolone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triancinolone 10 mg/ml intralesional injection
Trial: 14666354
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9% injection (placebo)
Trial: 7943838
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine 0.75% (6-8 ml)
Trial: 7943838
Drug: Intravenous bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bupivacaine (1.2 mg.min-1)
Trial: 7943838
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline (6-8 ml)
Trial: 3036980
Drug: Topical drops
RxNorm normalized name: benzyl alcohol 10 % TOPICAL DROPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical drops containing combinations of antibiotics and steroids (including one with an anti-fungal agent)
Trial: 31044759
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (15.2 g/day) after a low-salt diet (2.9 g/day) for 7 days each
Trial: 31044759
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (15.2 g/day)
Trial: 18097227
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily plus two nucleoside reverse transcriptase inhibitors
Trial: 18097227
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 300/75 mg/m twice daily
Trial: 16882678
Drug: Oral CoQ(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CoQ(10) (100 mg tid)
Trial: 14714358
Drug: Jiangya Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiangya Capsule (JYC)
Trial: 10813709
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy consisting of intraarterial cisplatin infusion (2 mg/kg every 8 weeks) and systemic interferon-alpha (3 million IU/m2 subcutaneously 3 times a week)
Trial: 10813709
Drug: Intraarterial cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial cisplatin infusion (2 mg/kg every 8 weeks)
Trial: 10813709
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha
Trial: 8782256
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of neomycin, polymyxin B, and dexamethasone
Trial: 1738550
Drug: Vestibular suppressant
RxNorm normalized name: Buckley's Cough Suppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular suppressant medication
Trial: 30572991
Drug: Non-intervention (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intervention (insulin treatment only)
Trial: 21073054
Drug: DEC (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (300 mg) + Doxycycline (200 mg)
Trial: 21073054
Drug: DEC (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC (300 mg) + Placebo
Trial: 28002105
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with ingenol mebutate gel, 0.015% after 3 weeks
Trial: 28002105
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with vehicle gel after 3 weeks
Trial: 21181475
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (100 mg/m², 1-hour infusion, weekly for 6 weeks)
Trial: 15149512
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 cream applied twice daily for 8 weeks
Trial: 15149512
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily for 8 weeks
Trial: 15149512
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 cream
Trial: 9048527
Drug: Sodium dodecyl
RxNorm normalized name: Sodium dodecyl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Trial: 8392210
Drug: Isoprenaline (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoprenaline (beta 1, beta 2, and beta 3-agonist)
Trial: 8392210
Drug: Nadolol 20
RxNorm normalized name: nadolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 20 mg (beta 1/beta 2 antagonist)
Trial: 8392210
Drug: Nadolol 5
RxNorm normalized name: bendroflumethiazide-nadolol 5 mg-40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 5 mg (beta 1/beta 2 antagonist)
Trial: 8392210
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg (beta 1 antagonist)
Trial: 2881423
Drug: Lower-dose alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose alfentanil groups
Trial: 24296871
Drug: Allopurinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200 mg/day) for 3 months
Trial: 18613385
Drug: Haemopressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemopressin (1 mg tri‐glycyl‐lysin‐vasopressin acetate, 2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Trial: 18613385
Drug: Glypressin (2mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glypressin (2mg i.v. immediately followed by 1 mg i.v. q4h for 5 days)
Trial: 16636120
Drug: Once-weekly (OW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly (OW) alendronate 70 mg
Trial: 16636120
Drug: Once-weekly (OW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly (OW) risedronate 35 mg
Trial: 8827792
Drug: Doxapram (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (0.5 mg/kg)
Trial: 1426825
Drug: Acamprosate (666
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (666 mg, 2 tablets)
Trial: 20007794
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetaminophen 500 mg and ibuprofen 150 mg per tablet (Maxigesic)
Trial: 20007794
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg per tablet alone
Trial: 20007794
Drug: Ibuprofen 150
RxNorm normalized name: Ibuprofen 150 mg and paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 150 mg per tablet alone
Trial: 12182272
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg fluoxetine per day
Trial: 12182272
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fluoxetine per day
Trial: 10190822
Drug: Glatiramer acetate,
RxNorm normalized name: Glatiramer Acetate, 20 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate, 20 mg/d
Trial: 8846544
Drug: Anti-TNF alpha
RxNorm normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF alpha monoclonal antibodies (mabs)
Trial: 8846544
Drug: Anti-T cell
RxNorm normalized name: Anti-T-lymphocyte immune globulin, rabbit
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-T cell therapies
Trial: 2178965
Drug: Theophylline (individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (individually titrated dose)
Trial: 28402454
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 160-80-40 mg subcutaneously
Trial: 28402454
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 2.5 mg/kg/day
Trial: 26506378
Drug: Gel-Acid (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-Acid (96 kcal whey protein gel)
Trial: 26506378
Drug: Gel-Heated (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-Heated (96 kcal whey protein gel)
Trial: 23936977
Drug: Intramuscular depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular depot medroxyprogesterone acetate (DMPA) therapy
Trial: 23936977
Drug: Severe pain
RxNorm normalized name: Orajel Severe Pain Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe pain prior to treatment
Trial: 21299465
Drug: Pamidronate (60‐90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (60‐90 mg once a month for 1 year)
Trial: 20439555
Drug: Iron-fortified pandesal
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified pandesal (hydrogen-reduced iron at 80 mg/kg, electrolytic iron at 80 mg/kg, or ferrous fumarate at 40 mg/kg)
Trial: 20439555
Drug: VA-fortified pandesal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VA-fortified pandesal (at 490 RE/100 g)
Trial: 17194963
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (ET) for 8 weeks
Trial: 9740926
Drug: Brompheniramine 8
RxNorm normalized name: brompheniramine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brompheniramine 8 mg
Trial: 3395665
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral dose of terodiline (Mictrol)
Trial: 3395665
Drug: Deuterated drug
RxNorm normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterated drug as a covariate
Trial: 27641967
Drug: Sitagliptin (50-100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50-100mg daily)
Trial: 25305273
Drug: Phytosterols intake
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols intake (average 296 mg/d)
Trial: 19455117
Drug: Extracorporeal albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal albumin dialysis (ECAD) plus standard medical therapy
Trial: 19455117
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy only
Trial: 16932229
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus NMBAs (n = 18)
Trial: 16932229
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus placebo (n = 18)
Trial: 15384020
Drug: DMSA, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMSA, 2.5 mg/kg/d for 8 weeks